-
TNM Classification: What We’ve Learned and Where We’re Going
Experts at WCLC 2026 outlined important takeaways from the 9th Edition TNM Classification, as well as key priorities for the 10th Edition.
More News from #WCLC26
-
DeLLphi-309: Tarlatamab Extended-Interval Dosing Demonstrates Comparable Efficacy in Patients With SCLC
Dr. Jonathan Goldman said dosing regimens in which tarlatamab was administered every three or four weeks were efficacious and had safety profiles comparable to the currently approved schedule.
-
Class III BRAF Alterations Associated With Shorter Survival in Stage IV NSCLC Following Immunotherapy
Dr. Alessandro Di Federico said results from a retrospective study suggest that patients with BRAF class II and III alterations have distinct clinicopathologic features and co-mutation patterns.
